1. Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.12
Figure 2 Heterogeneity in bleeding criteria and time of randomization (TOR) in individual trials
Figure 2 | Heterogeneity in bleeding criteria and time of randomization (TOR) in individual trials. a | Trial heterogeneity in bleeding criteria and incidence of bleeding, and b | in the TOR that might account for under-reporting of events. The details of primary end points are described in Table 2. The primary end point ranged from standard major adverse cardiac events combined with bleeding (net adverse cardiac events, NACE) or not combined with bleeding (non-NACE). BARC, Bleeding Academic Research Consortium; DAPT, dual antiplatelet therapy; GUSTO, Global Use of Strategies to Open Occluded Arteries; ISTH, International Society on Thrombosis and Haemostasis bleeding scale; STEEPLE, Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomized Evaluation; TIMI, Thrombolysis in Myocardial Infarction.
Miyazaki, Y. et al. (2017) Single or dual antiplatelet therapy after PCI
Nat. Rev. Cardiol. doi: /nrcardio